"Can you confirm that our 'improved cognition' is unlike that of aducanumab where the "improved cognition" is actually a slowed cognitive degradation vs placebo? 158% improved cognition = actual improvements in cognitive function vs baseline?"

Yes, improvement vs. baseline and vs. placebo. Looks like in the sub-group with baseline MoCA<22, the apabetalone treated patients went from average of ~18 at baseline to ~20 at 52 weeks and ~22 at end of study. Placebo group paralled the improvement at 52 weeks, but then the apabetalone group diverged from placebo by end of study for a MoCA score difference of about 2 points by end of study.

See slides 4, 5 and 6

http://118009.choruscall.com/resverlogix/resverlogix20191206.pdf